*ST双成(002693.SZ):注射用比伐芦定获得澳大利亚药物管理局(TGA)上市许可

智通财经
May 06

智通财经APP讯, *ST双成(002693.SZ)发布公告,公司于近日收到澳大利亚药物管理局(TGA)签发的注射用比伐芦定的上市许可。

据称,注射用比伐芦定用作抗凝剂。治疗中高风险急性冠状动脉综合征(ACS)(不稳定型心绞痛/非ST段升高型心肌梗死(UA/NSTEMI)且正接受早期侵入性治疗的患者,以及正在接受经皮冠状动脉介入治疗(PCI)的患者。注射用比伐芦定拟与阿司匹林联合使用。此外,可联合P2Y12拮抗剂使用(例如氯吡格雷或噻氯匹定)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10